Real-world Outcomes of First-line Platinum-based Chemotherapy in Patients Aged 80 Years or Older With Metastatic Urothelial Carcinoma
Background/Aim As populations age, more patients aged ≥80 years with metastatic urothelial carcinoma (mUC) require systemic therapy. However, the efficacy and safety of first-line platinum-based chemotherapy (PBC) in octogenarians remain unclear. This study aimed to describe clinical outcomes in patients aged ≥80 years...